AFFILIATIONS
1 Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York, United States
2 Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York, United States, Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York, United States
ABSTRACT
Background:
Many adults with iron deficiency anemia (IDA) require replacement doses substantially exceeding 1 g. Yet currently available IV iron formulations generally limit single-infusion dosing to approximately 1g, requiring multiple visits to achieve complete iron replacement. A safe and effective 1.5 g single-infusion regimen could improve convenience, reduce healthcare utilization, and facilitate completion of therapy.
The "Georgetown regimen" established the safety of administering 1 g of low-molecular-weight iron dextran over one hour and has become a de facto standard for total-dose infusion. However, the rationale for limiting single-infusion dosing to 1 g is not well defined, and there is little physiologic rationale to suggest that this dose represents a threshold beyond which toxicity would be expected to increase.
Because infusion-related reactions, including the Fishbane reaction, are thought to relate primarily to infusion rate rather than total iron dose, administration of 1.5 g over two hours represents a conservative extension of this approach. This approach has been adopted at our institution.
Methods:
We retrospectively evaluated consecutive patients treated with 1.5 g of low-molecular-weight iron dextran, administered intravenously over two hours (ID-SDI). Patient characteristics, infusion-related adverse events, and hematological response were assessed.
Results:
From July 2025 through May 2026, ID-SDI was scheduled for 53 patients; 49 completed treatment and were included in the analysis.
Heavy menstrual bleeding accounted for most cases (35/49), 8 had suspected GI blood loss, 2 were pregnant, and in 3 the etiology of IDA was unknown.
Pre-treatment baseline hemoglobin averaged 8.39 ± 1.07 g/dL (range, 6.5–10.9 g/dL), and calculated iron deficits (Ganzoni formula, target Hb 12 g/dl) averaged 1,298 ± 280 mg (range, 739–2,203 mg).
Iron dextran was administered in the usual manner, starting with a 25 mgs test dose, after which the remainder of the 1500 mg was administered over 2 hours.
No serious infusion reactions were reported.
Among 31 patients with at least one Hb measurement within 3 months of infusion, mean Hb increased from 8.16 g/dL at referral to 11.57 g/dL, corresponding to a mean increase of 3.41 ± 1.11 g/dL (range, 1.3–5.7 g/dL). The mean interval from infusion to follow-up hemoglobin assessment was 56.1 ± 18.2 days.
As a descriptive comparison, outcomes were examined in a historical cohort assigned to treatment with ferric carboxymaltose (FCM) 750 mg × 2. Insurance authorization for FCM was denied in 8/66 patients (12%). Forty-four of the 55 authorized patients, (80%) completed both FCM infusions.
Among the 30 patients with follow-up Hb measurements, mean Hb increased from 7.79 to 11.88 g/dL (mean increase 4.09 ± 1.51 g/dL). Follow-up intervals were similar between cohorts (57.3 vs 56.1 days). After adjustment for baseline Hb and follow-up interval, iron formulation was not independently associated with Hb response (β = 0.38 g/dL favoring FCM; 95% CI −0.15 to 0.91; p = 0.15).
Conclusions:
Administration of 1.5 g of low-molecular-weight iron dextran over two hours is well tolerated and effectively corrected iron deficiency in this cohort. Given that many patients require substantially more than 1 g of iron replacement, this regimen represents a pragmatic single-visit alternative to multi-infusion strategies.
A single 1.5 g iron dextran infusion also offers an alternative to ferric carboxymaltose 750 mg × 2, avoiding a second infusion visit, reducing treatment delays associated with insurance authorization, and eliminating the risk of ferric carboxymaltose-associated hypophosphatemia.
These findings support prospective evaluation of higher-dose single-infusion iron dextran regimens with standardized laboratory follow-up, as a means of improving convenience, reducing healthcare utilization, and facilitating complete iron repletion without compromising safety.
DISCLOSURES
Mark Chaitowitz, MD: No relevant conflicts of interest to declare.